翰森制药 | 圣罗莱®获《延缓慢性肾脏病进展临床管理指南（2025 年版）》推荐

参考文献：

[1] 延缓慢性肾脏病进展临床管理指南（2025年版）[J]. 中华肾脏病杂志, 2025, 41(6): 455-488.

[2] Xie,Jianteng et al. Randomized Trial of Pegmolesatide for the Treatment of Anaemia in Patients with Non-Dialysis Chronic Kidney Disease. Kidney International Reports.2024.https://doi.org/10.1016/j.ekir.2024.12.002. In Press.

[3]长效红细胞生成刺激剂治疗肾性贫血中国专家共识（2024年版）[J]. 中华肾脏病杂志,2024,40(2):146-157.

[4]指导肾性贫血患者自我管理的中国专家共识(2024 版). 中国血液净化.2025,24(1):1-12

[5]Xie,Jianteng et al. Randomized Trial of Pegmolesatide for the Treatment of Anaemia in Patients with Non-Dialysis Chronic Kidney Disease. Kidney International Reports.2024.https://doi.org/10.1016/j.ekir.2024.12.002. In Press.

[6]Xueqing Yu,et al. Pegmolesatide for the Treatment of Anemia in Non-dialysis-dependent Chronic Kidney Disease Patients: Post-hoc Analysis of a Phase 3 Trial. WCN 2025. Abstract No: WCN25-679.